The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and mitigated.
All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:
- All financial relationships with Commercial Companies that contributors have had within the pre¬vious 24 months. A commercial company is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.
- Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.
The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 24 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be mitigated prior to the delivery of the activity.
Financial Relationship Disclosure
For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor by:
- Direct or indirect compensation;
- Ownership of stock in the producing company;
- Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
- Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies.
Description of Financial Interests
Code |
Description |
C |
Consultant/Advisor Consultant fee, paid advisory boards, or fees for attending a meeting. |
E |
Employee Hired to work for compensation or received a W2 from a company. |
L |
Lecture Fees/Speakers Bureau Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company. |
P |
Patents/Royalty Beneficiary of patents and/or royalties for intellectual property. |
S |
Grant Support Grant support or other financial support from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies. Research funding should be disclosed by the principal or named investigator even if your institution receives the grant and manages the funds. |
EE |
Employee, Executive Role Hired to work in an executive role for compensation or received a W2 from a company. |
EO |
Owner of Company Ownership or controlling interest in a company, other than stock. |
SO |
Stock Options Stock options in a private or public company. |
PS |
Equity/Stock Holder - Private Corp (not listed on the stock exchange) Equity ownership or stock in privately owned firms, excluding mutual funds. |
US |
Equity/Stock Holder - Public Corp (listed on the stock exchange) Equity ownership or stock in publicly traded firms, excluding mutual funds. |
I |
Independent Contractor Contracted work, including contracted research |
Disclosure list contains individual’s relevant disclosures with ineligible companies. All relevant financial relationships have been mitigated.
Secretary for Annual Meeting
Name |
Disclosure |
Maria M Aaron MD |
None |
Annual Meeting Program Committee
The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Scientific Papers/Posters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.
Associate Secretary for the Annual Meeting Program |
Disclosure |
Bennie H Jeng MD |
EyeGate Pharmaceuticals Inc.: O; GlaxoSmithKline: C; Kedrion: C; Merck & Co., Inc.: C; Oyster point: C; Sanofi: C |
Annual Meeting Program Committee |
Nicole R Fram MD |
Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corporation: L; Johnson & Johnson Vision: L,C; LENSAR: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S |
Jessica B Ciralsky MD |
NONE |
Paula Anne Newman-Casey MD |
NONE |
Andrew G Lee MD |
Horizon: C |
Jonathan W Kim MD |
NONE |
Martha P Schatz MD |
NONE |
Elizabeth Yeu MD |
Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Allergan, Inc.: C,L; Aurion: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; CorneaGen: C; Dompe: C; Expert Opinion: C; Glaukos Corporation: C,L; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C,S; Katena Products, Inc: C; LENSAR: C; Melt: C; Novartis Pharma AG: C; OCuSOFT, Inc.: C; ScienceBased Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus: C,S; THEA: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S; Visus: C |
Sharon D Solomon MD |
NONE |
Subcommittee for: Cataract
Chair |
Disclosure |
Nicole R Fram MD |
Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corporation: L; Johnson & Johnson Vision: L,C; LENSAR: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S |
Subcommittee Members |
Surendra Basti MBBS |
Johnson & Johnson Vision: C |
Sathish Srinivasan MBBS |
AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; DORC International, bv/Dutch Ophthalmic, USA: C; Medicontur: C; Scope Ophthalmics: C; THEA: L; Zeiss: C |
Subcommittee Reviewers |
Brandon Ayres MD |
Alcon Laboratories, Inc.: C,L; Allergan: C,L; Bausch+Lomb: L; Carl Zeiss Inc: C; CorneaGen: C; Dompe: C,L; Glaukos Corporation: C; New World Medical Inc: C; Novartis, Alcon Pharmaceuticals: C; Rayner Intraocular Lenses Ltd: C; Sun Ophthalmics: C,L |
Kourtney A Houser MD |
Abbvie: C; Avellino Labs: C; Bausch and Lomb: C; Novartis, Alcon Pharmaceuticals: C; RVL pharmaceuticals: C |
Sumitra S Khandelwal MD |
Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala Pharmaceuticals, Inc.: C; Ocular Therapeutix: C |
Jeremy Z Kieval MD |
Alcon Laboratories, Inc.: C; Dompe: C; Johnson & Johnson: C,L; Kala: C,L; LENSAR: C; Novartis Pharma AG: C; Ocular Therapeutix: C; Sun Ophthalmics: C; Tarsus: C; Visus: C |
Steven M Naids MD |
Allergan, Inc.: C,L; Bausch + Lomb: L; Eyevance: C |
Subcommittee for: Cornea, External Disease
Chair |
Disclosure |
Jessica B Ciralsky MD |
NONE |
Subcommittee Members |
Anat Galor MD |
Allergan: C; Astrozenica: C; Dompe: C; Novaliq: C; Novartis Pharma AG: C; Oculis: C; Oyster Point: C; Shire: C; Tarsus: C |
Elmer Y Tu MD |
Daiichi Sankyo: C; Dompe: C; GlaxoSmithKline: C; Oyster Point: C; Santen, Inc.: C |
Subcommittee Reviewers |
Vatinee Y Bunya MD |
NONE |
Asim V Farooq MD |
Ambrx: C; Amgen Inc: C; Daiichi-Sankyo: C; Eisai: C; GlaxoSmithKline: C; Sanofi: C; Seagen: C |
Christina R Prescott MD |
Johnson & Johnson Vision: C; Santen, Inc.: C |
Jennifer R Rose-Nussbaumer MD |
NONE |
Christopher S Sales MD |
Network Medical: P |
Subcommittee for: Glaucoma
Chair |
Disclosure |
Paula Anne Newman-Casey MD |
NONE |
Subcommittee Members |
Brian C Samuels MD PhD |
Heidelberg Engineering: S |
John T Lind MD |
Abbvie: S; Heru: S; Nicox: S |
Subcommittee Reviewers |
Jenny Chen MD |
NONE |
Natasha Nayak Kolomeyer MD |
Abbvie: C,S; Aerie Pharmaceuticals, Inc.: S; Alimera Sciences, Inc.: C; Allergan, Inc.: C,S; Diopsys, Inc.: S; Equinox: S; GENENTECH: C; Glaukos Corporation: S; Guardion Health Sciences: S; Nicox: S; Olleyes: S; Regeneron Pharmaceuticals, Inc.: C; Santen: S |
Ahmara G Ross MD |
Gene Therapy for Ocular Disorders (Patent Number 16/607,834, 2019): P; Gyroscope Therapeutics: C,I; Noveome: C,P,S |
Catherine Q Sun MD |
NONE |
Luis E Vazquez MD |
NONE |
Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History, Vision Rehabilitation and Wellness
Chair |
Disclosure |
Andrew G Lee MD |
Horizon: C |
Subcommittee Members |
John J Chen MD PHD |
Horizon: C; Roche Diagnostics: C; UCB: C |
Julie Falardeau MD |
NONE |
Subcommittee Reviewers |
Nagham Al-Zubidi MD |
NONE |
Shauna E Berry DO |
NONE |
Courtney E Francis MD |
NONE |
Y Joyce Liao MD PhD |
AmMaxBio: C |
Claudia Maria Prospero Ponce MD |
NONE |
Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit
Chair |
Disclosure |
Jonathan W Kim MD |
NONE |
Subcommittee Members |
Sara T Wester MD |
Horizon Therapeutics: C; immunovant: C; Vasaragen: C |
Michael K Yoon MD |
Horizon: US |
Subcommittee Reviewers |
Malena M Amato MD |
NONE |
Anne Barmettler MD |
NONE |
Steven M Couch MD |
NONE |
Catherine J Hwang MD |
NONE |
Kenya M Williams MD |
NONE |
Subcommittee for: Pediatric Ophthalmology, Strabismus
Chair |
Disclosure |
Martha P Schatz MD |
None |
Subcommittee Members |
Stacy L Pineles MD |
Asteroid 3D: S; fitz frames: C; horizon surgical: PS |
Federico G Velez MD |
Luminopia: S; Nevakar: C; Novartis: C,S; Viridian: S |
Subcommittee Reviewers |
Sean P Donahue MD PhD |
Gensight: C; Olleyes: C,PS |
Judith E Gurland MD |
NONE |
Tina Rutar MD |
Sydnexis: S,SO,C |
Ujwala Saboo MD |
NONE |
Mitchell B Strominger MD |
NONE |
Subcommittee for: Refractive Surgery and Optics, Refraction, Contact Lenses
Chair |
Disclosure |
Elizabeth Yeu MD |
Advanced Vision Group: C; Alcon Laboratories, Inc.: C,L; Allergan, Inc.: C,L; Aurion: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C,L; BlephEX, LLC: C; Bruder Healthcare Company: C; BVI: C; Carl Zeiss Meditec: C,L; CorneaGen: C; Dompe: C; Expert Opinion: C; Glaukos Corporation: C,L; Johnson & Johnson Vision: C,L; Kala Pharmaceuticals, Inc.: C,S; Katena Products, Inc: C; LENSAR: C; Melt: C; Novartis Pharma AG: C; OCuSOFT, Inc.: C; ScienceBased Health: C; Sight Sciences, Inc.: C; STAAR Surgical: C; Surface: C; Tarsus: C,S; THEA: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S; Visus: C |
Subcommittee Members |
Edward E Manche MD |
Alcon Laboratories, Inc.: S; Allergan: S; Averdro: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Guidepoint: C; Johnson & Johnson Vision: C,S; KKR: C; Novartis Pharma AG: S; Placid0: PS,SO; Presbia, Inc.: S; RxSight: US; VacuSite: P,PS |
J Bradley Randleman MD |
NONE |
Subcommittee Reviewers |
Kathryn Masselam Hatch MD |
Alderya Therapeutics, Inc.: C; Carl Zeiss Meditec: C; cxlo: C; Glaukos Corporation: C,US; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: C; Sun Ophthalmics: C |
Brad E Kligman MD |
Dompe: S |
Brian M Shafer MD |
Alcon Laboratories, Inc.: C; Allergan, Inc.: L; Equinox: C |
Denise M Visco MD |
Bausch + Lomb: C; Bruder Healthcare Company: C; Carl Zeiss Inc: C,L; Cassini USA, Inc.: C; LENSAR: C,L; Omeros: C,L; Oyster Point Pharma: C; Sun Pharmaceuticals: C,L |
Dagny C Zhu MD |
Alcon Laboratories, Inc.: C,S; Allergan: L; Johnson & Johnson Vision: C; LENSAR: C |
Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation
Chair |
Disclosure |
Sharon D Solomon MD |
NONE |
Subcommittee Members |
Anita Agarwal MD |
NONE |
Sunir J Garg MD FACS |
Allergan, Inc.: C; Apellis Pharmaceuticals, Inc.: S; Bausch+Lomb: C; Boehringer Ingelheim: C,S; Coherus: C; Johnson & Johnson: C; Kodiak: S; Merck Manual: C; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S |
Subcommittee Reviewers |
Mark Philip Breazzano MD |
NONE |
Roomasa Channa MD |
NONE |
Jay K Chhablani MBBS |
Abbvie: L; Allergan, Inc.: L; Novartis Pharma AG: C; Salutaris: C |
Yannis Mantas Paulus MD |
Hedgefog Research Inc: C; IRIDEX: C; MediBeacon: C; PhotoSonoX LLC: PS,EO,P |
Alice Yang Zhang MD |
NONE |
Thomas A Albini MD |
Adverum Biotechnologies: C; Applied Genetic Technologies Corporation: C; Bausch+Lomb: C; Beaver Visitec: C; Clearside: C; Eyepoint Pharmaceuticals, Inc.: C; GENENTECH: C; Mallinckrodt: C; Novartis, Alcon Pharmaceuticals: C; RegenexBio: C |
Bryn M Burkholder MD |
NONE |
John A Gonzales MD |
UCSF AutoImmunoprofiler: S |
Jaclyn L Kovach MD |
Novartis Pharma AG: L; Regeneron Pharmaceuticals, Inc.: L |
Jennifer E Thorne MD PhD |
AbbVie: C; ClearView: C; Gilead Sciences: C; Guidepoint: C; Roche Diagnostics: C; Tarsier Pharma: C,SO |
Special Projects Committee
The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.
Associate Secretary |
Disclosure |
Carolyn K Pan MD |
NONE |
Committee Members |
John J DeStafeno MD |
Sun Ophthalmics: L |
Laura B Enyedi MD |
Nevakar: C; novartis: C; Tarsus: C |
Collin M McClelland MD |
Horizon Therapeutics: C |
Beeran B Meghpara MD |
Allergan, Inc.: C,L; Carl Zeiss Meditec: C; CorneaGen: C; Dompe: L,C; Eyevance Pharmaceuticals: C,L; Glaukos Corporation: C; Johnson & Johnson Vision: C; Kala Pharmaceuticals, Inc.: L,C; Oculus, Inc.: C; Sight Sciences, Inc.: C; Sun Ophthalmics: C,L; Tarsus: C; W.L Gore & Associates: C |
Rachel K Sobel MD |
Guidepoint: C |
Kateki Vinod MD |
NONE |
Skills Transfer Advisory Committee
The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.
Associate Secretary |
Disclosure |
Michael L Savitt MD |
NONE |
Advisory Members |
Brock K Bakewell MD |
AcuFocus, Inc.: S; Johnson & Johnson Vision: S |
Cat Burkat MD FACS |
NONE |
Clara C Chan MD |
Abbvie: C,L; Aequus Pharmaceuticals: C; Allergan, Inc.: C,L,S; Daichii: C; Dompe: C; Johnson & Johnson Vision: C,US; Labtician Ophthalmics, Inc.: L; Novartis Pharma AG: C,S; Pfizer, Inc.: US; Santen, Inc.: C; Sun Ophthalmics: C; THEA: C,L; zeiss: C |
Brian A Francis MD |
Aerie Pharmaceuticals, Inc.: C,L; Alcon Laboratories, Inc.: C,S; Allergan, Inc.: C,S; Beaver-Visitec International, Inc.: C; Greybug: C; IRIDEX: C; Istar: C; MicroSurgical Technology: C |
Anjali Tannan MD |
NONE |
Keye L Wong MD |
NONE |
Subspecialty Day Advisory Committee
Associate Secretary |
Disclosure |
R Michael Siatkowski MD |
NONE |
Advisory Members |
Bonnie An Henderson MD |
Alcon Laboratories, Inc.: C; Allergan, Inc.: C; Horizon: C |
Michael S Lee MD |
horizon: US; panbela: C; Pfizer, Inc.: US; springer: P; uptodate: P |
Jennifer Irene Lim MD |
Adverum Biotechnologies: S; Alderya Therapeutics, Inc.: S; Allergan, Inc.: C; Aura Biosciences: C; Chengdu Kanghong: S; Cognition Therapeutics: C; CRC Press/ Taylor and Francis: P; Eyenuk: C; GENENTECH: C,S,L; Greybug: S; Iveric Bio: C; JAMA Ophthalmology Editorial Board: C; Luxa: C; NGM: S; Novartis Pharma AG: C; Opthea: C; Quark: C; Regeneron Pharmaceuticals, Inc.: C,S; Santen, Inc.: C; Stealth: S; Unity: C; Viridian: C |
Shahzad I Mian MD |
Andover Eye Associates: S; Kowa American Corporation: S; Novartis: S; Vision care: S |
Jody R Piltz MD |
Aerie Pharmaceuticals, Inc.: C,L |
Subspecialty Day
Cornea
Program Directors |
Disclosure |
Vishal Jhanji MD |
NONE |
Sonal S Tuli MD |
NONE |
Christina Prescott MD |
Johnson & Johnson Vision: C; Santen, Inc.: C |
Program Planning Group |
Vishal Jhanji MD |
NONE |
Sonal S Tuli MD |
NONE |
Christina Prescott MD |
Johnson & Johnson Vision: C; Santen, Inc.: C |
Glaucoma
Program Directors |
Disclosure |
Kelly Walton Muir MD |
NONE |
Teresa C Chen MD |
NONE |
Program Planning Group |
Robert T. Chang, MD |
Aerie Pharmaceuticals, Inc.: C; Alcon Laboratories, Inc.: C; Equinox: C; Genentech: C,S; Ocular Therapeutix: C; Omeros Corp.: C |
Babak Eliassi-Rad, MD |
NONE |
Ronald Leigh Fellman MD OCS |
NONE |
Christopher A. Girkin, MD, MSPH |
Amydis, Inc.: C,SO; Heidelberg Engineering: C,S; Topcon Medical Systems, Inc.: C,S |
Lily T. Im, MD |
NONE |
Robert J. Noecker, MD, MBA |
AbbVie: C,L; Alcon Laboratories, Inc.: C,L; Bausch + Lomb: C,L; Beaver-Visitec International, Inc.: C; Glaukos Corp.: C,S; Iridex: C,L; New World Medical, Inc.: L,C; Ocular Therapeutix: C,SO; Santen, Inc.: C; Sight Sciences, Inc.: C,SO,L; Thea: C |
Manjool M. Shah, MD |
Allergan: C; Glaukos Corp.: C; Ivantis: C; Katena Products, Inc.: C; ONL Therapeutics: C |
Ramya N. Swamy, MD, MPH |
NONE |
Luis E. Vazquez, MD, PhD |
New World Medical, Inc.: L |
Oculofacial Plastic Surgery
Program Directors |
Disclosure |
Thomas Edward Johnson MD |
NONE |
Cat Burkat MD FACS |
NONE |
Program Planning Group |
Thomas Edward Johnson MD |
NONE |
Cat Burkat MD FACS |
NONE |
Pediatric Ophthalmology
Program Directors |
Disclosure |
David K. Wallace, MD MPH |
NONE |
David G. Morrison, MD |
NONE |
Program Planning Group |
Robert A. Clark, MD |
NONE |
David K. Coats, MD |
NONE |
Sergul A. Erzurum, MD |
NONE |
Sharon F. Freedman, MD |
Qlaris Bio: C |
Nandini G. Gandhi, MD |
NONE |
Amy K. Hutchinson, MD |
NONE |
David G. Morrison, MD |
NONE |
Deborah K. VanderVeen, MD |
Ocular Therapeutix: S |
David K Wallace MD MPH |
NONE |
Refractive Surgery
Program Directors |
Disclosure |
Deepinder K Dhaliwal MD |
Allergan, Inc.: C; Glaukos: S; Haag-Streit Group: C; Johnson & Johnson: C; Kowa American Corporation: S; Lenz Therapeutics: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: C,L; STAAR Surgical: L; TearSolutions: C; Trefoil: C |
Jodhbir S Mehta MBBS |
NONE |
Program Planning Group |
Renato Ambrosio, Jr., MD |
Alcon Laboratories, Inc.: C; Allergan: L; Carl Zeiss, Inc.: L; Essilor Instruments: L; Genom: C,L; Mediphacos: L; Oculus, Inc.: C |
J. Burkhard Dick, MD |
AcuFocus, Inc.: C,SO; Bausch + Lomb: L; EuroEyes: C; Johnson & Johnson Vision: C; Morcher GmbH: P; Oculus Surgical, Inc.: P; RxSight Inc.: C |
Deepinder K Dhaliwal MD |
Allergan, Inc.: C; Glaukos: S; Haag-Streit Group: C; Johnson & Johnson: C; Kowa American Corporation: S; Lenz Therapeutics: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: C,L; STAAR Surgical: L; TearSolutions: C; Trefoil: C |
Nicole Fram, MD |
Alcon Laboratories, Inc.: C; Avellino Labs: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,L,SO; Glaukos Corp.: L; Johnson & Johnson Vision: L,C; Lensar: C; Ocular Science: SO,C; Ocular Therapeutix: S; Orasis Pharmaceuticals: C,SO; OysterPoint: C; RxSight: L,C; Vital Tears: L; Zeiss: C,L,S |
Bonnie An Henderson, MD |
Alcon Laboratories, Inc.: C; Allergan, Inc.: C; Horizon: C |
Jodhbir S Mehta MBBS |
NONE |
J. Bradley Randleman, MD |
NONE |
Retina
Program Directors |
Disclosure |
Srinivas R Sadda MD |
4DMT: C; Alexion: C; Allergan: C; Amgen Inc: C; Apellis Pharmaceuticals, Inc.: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Gyroscope: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Jannsen: C; Nanoscope: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Pfizer, Inc.: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L |
Timothy G Murray MD MBA |
Alcon Laboratories, Inc.: C; FDA: C |
Program Planning Group |
Sophie J. Bakri, MD |
AbbVie: C; Adverum: C; Alimera Sciences, Inc.: C; Allergan: C; Apellis Pharmaceuticals, Inc.: C; Eyepoint: C; Genentech: C; Ilumen: C; Iveric Bio: C; Kala Pharmaceuticals, Inc.: C; Novartis; Alcon Pharmaceuticals: C; Outlook Therapeutics: C; Pixium: C; Regenxbio: C,S; ReVana: SO; Roche: C; VoxelCloud: SO; Zeiss: C |
Barbara Ann Blodi, MD |
NONE |
Timothy G Murray MD MBA |
Alcon Laboratories, Inc.: C; FDA: C |
Srinivas R Sadda MD |
4DMT: C; Alexion: C; Allergan: C; Amgen Inc: C; Apellis Pharmaceuticals, Inc.: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Gyroscope: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Jannsen: C; Nanoscope: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Pfizer, Inc.: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L |
Uveitis
Program Directors |
Disclosure |
Russell W Read MD PhD |
NONE |
Lucia Sobrin MD |
NONE |
Program Planning Group |
Wendy M. Smith, MD |
NONE |
Kathryn L. Pepple, MD, PhD |
NONE |
Edmund Tsui, MD |
Cylite Pty, Ltd.: S; EyePoint Pharmaceuticals: C; Kowa Company, Ltd.: C,S; Pfizer, Inc.: S |
Stephanie M. Llop Santiago, MD |
NONE |
Ann-Marie Lobo, MD |
Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Neolight: C; Phoenix Technology Group: C; Siloam Vision: C |
AAOE Content Committee
The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.
Chair |
Disclosure |
Natalie M Loyacano COMT ROUB OSA OCSR (F)ATPO |
None |
Committee Members |
Stephanie Collins Mangham MBA COA OCSR |
Regeneron Pharmaceuticals, Inc.: C,L |
Tori Elkins COT MBA |
NONE |
Brett D Gerwin MD |
NONE |
Sondra Hoffman COE CPE CMPE HRM |
Hoffman Consulting Group: EE |
Anthony Pruett Johnson MD FACS |
NONE |
Bansari Mehta MHA |
NONE |
Christine M McDonald COE COA ROUB OSC CTC OCS |
NONE |
Heather Modjesky COE |
NONE |
Savory A Turman COMT |
NONE |
Academy Staff
Name |
Disclosure |
Debra Rosencrance |
NONE |
Melanie Rafaty |
NONE |
Sangeeta Fernandes |
NONE |
Ann L'Estrange |
NONE |
Susan Oslar |
NONE |
Elizabeth Washburn |
NONE |
Licia Wells |
NONE |
Julia Fennell |
NONE |
Sadie Peckens |
NONE |